The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I didn't write to my MP as a shareholder but as a constituent keen for a promising treatment to be elevated and supported.
And I have posted about SNG001 on all my social media pages as well as the home trial invitation link from Synairgen's FB page. Not desperate and dignity intact.
I have tried again ... we should all be doing this, again and again. My thanks to previous posters for text ideas:
Dear xxx,
I wrote to you on October 16th and 19th asking you to pursue this question with the Secretary of State for Health.
With the exception of the US drug Remdesivir, which has been shown to be largely ineffective, our government as well as the media appear to be interested only in the progress of vaccines, but not in the treatments which are also desperately needed.
Southampton company Synairgen's SNG001 is a nebuliser containing a natural substance (interferon beta 1a) that is simply inhaled directly into the lungs. It had spectacular results in its phase 2 trial, where it stopped Covid-19 in its tracks for 79% of those hospitalised patients who were given it, and from that and other trials, we know that it is safe.
A phase 3 trial across 20 countries involving 900 patients starts in November.
This treatment has the potential to keep patients both at home and in care homes from needing hospital admission and to lead to far better outcomes. Its use in hospitals would also dramatically reduce the number of patients requiring intensive care.
I ask you again: why is our government still silent on this treatment for Covid19?
Kind regards,
And Synairgen's own web site invites at-home, COVID-positive people to particptae:
https://www.covidtrialathome.com/
No reply from my MP (wrote to him twice) but after two emails addressed to Matt Han****, this response today. How can they use so many words but end up saying nothing? A special talent. Pathetic.
"Our ref: DE-1264250
Thank you for your correspondence of 13 October about potential COVID-19 treatments. I have been asked to reply.
COVID-19 is a novel virus, and it is crucial that the Government does everything possible to identify safe and effective treatment for those who need it.
Clinical trials are a vital part of this identification process, because they generate evidence for potential treatments. A number of trials are already underway in the UK and are testing a wide range of potential treatments in primary, acute and intensive care settings. This includes the RECOVERY trial, which is the world’s largest randomised control trial for COVID-19. This trial recently identified the first treatment in the world, dexamethasone, to reduce the risk of mortality in patients hospitalised with COVID-19 who require oxygen or ventilator support.
The Government is of course interested in learning more about all potential interventions that could be safe and effective in treating COVID-19. Further drugs, including novel compounds, will be included in new trials or added to existing trials based on rigorous assessment of the evidence available.
The identification of potential treatments to enter into UK trials is being coordinated by the Department of Health and Social Care. Anyone who would like their proposal to be considered for UK clinical trials can contact the Therapeutics Taskforce at therapeuticstaskforce@dhsc.gov.uk, providing any supporting evidence available for the proposal.
I hope you find this information helpful.
Yours sincerely,
Noor Safi
Ministerial Correspondence and Public Enquiries
Department of Health and Social Care"
I have asked:
“Southampton company Synairgen is about to start Phase III trials in hospitals across 20 countries of SNG001, a nasal spray delivering Interferon Beta-1a straight to the lungs, following highly encouraging Phase II results.
Can anyone explain why (apart from a press blip in July) this exciting treatment is rarely mentioned in the press and never in parliament?"
The registration confirmation email includes the line: "Please submit any questions to: garys@gsmultimedia.co.uk" Just getting an SNG question ready to send. What impact might it have if numerous SNG questions arrived?